Mef2c deletion in osteocytes results in increased bone mass

Journal of Bone and Mineral Research

Volumn 27, Issue 2, 2012, Pages 360-373

  Kramer, Ina ^a   Baertschi, Stefan ^a   Halleux, Christine ^a   Keller, Hansjoerg ^a   Kneissel, Michaela ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

BONE RESORPTION; CONDITIONAL KNOCKOUT MOUSE MODEL; Mef2c; OSTEOCYTE; SOST

Indexed keywords

MYOCYTE ENHANCER FACTOR 2; OSTEOPROTEGERIN; SCLEROSTIN;

ANIMAL CELL; ARTICLE; BONE DENSITY; BONE MASS; CONTROLLED STUDY; CORTICAL BONE; FEMALE; GENE DELETION; GENE EXPRESSION; IN VIVO STUDY; LONG BONE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOCYTE; SKELETON;

EID: 84856154871     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1492     Document Type: Article

References (61)

1. Dallas SL, Bonewald LF,. Dynamics of the transition from osteoblast to osteocyte. Ann NY Acad Sci. 2010; 1192: 437-43.
2. Rochefort GY, Pallu S, Benhamou CL,. Osteocyte: the unrecognized side of bone tissue. Osteoporos Int. 2010; 21: 1457-69.
3. Bonewald LF,. The amazing osteocyte. J Bone Miner Res. 2011; 26: 229-38.
4. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL,. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010; 87: 99-107.
5. Balemans W, Patel N, Ebeling M, Van HE, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van HW,. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002; 39: 91-7. (Pubitemid 34146376)
6. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME,. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002; 110: 144-52.
7. Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van HW,. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10: 537-43. (Pubitemid 32184286)
8. Brunkow ME, Gardner JC, Van NJ, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J,. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68: 577-89. (Pubitemid 32202753)
9. Piters E, Culha C, Moester M, Van BR, Adriaensen D, Mueller T, Weidauer S, Jennes K, de FF, Lowik C, Timmermans JP, Van HW, Papapoulos S,. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum Mutat. 2010; 31: E1526-43.
10. Kramer I, Loots GG, Studer A, Keller H, Kneissel M,. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010; 25: 179-89.
11. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C,. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23: 860-9. (Pubitemid 351768804)
12. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L,. Sclerostin mediates bone response to mechanical unloading via antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 2009; 24: 1651-61.
13. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL,. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146: 4577-83. (Pubitemid 41446595)
14. Genetos DC, Toupadakis CA, Raheja LF, Wong A, Papanicolaou SE, Fyhrie DP, Loots GG, Yellowley CE,. Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem. 2010; 110: 457-67.
15. Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y,. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development. 2008; 135: 3801-11.
16. Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM, Mishina Y,. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res. 2010; 25: 200-10.
17. Keller H, Kneissel M,. SOST is a target gene for PTH in bone. Bone. 2005; 37: 148-58. (Pubitemid 40962421)
18. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H,. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res. 2007; 22: 1957-67. (Pubitemid 351229312)
19. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM,. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005; 15: 928-35. (Pubitemid 40994212)
20. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH,. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008; 283: 5866-75.
21. Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA,. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone. 2004; 35: 448-54. (Pubitemid 38953192)
22. Kramer I, Keller H, Leupin O, Kneissel M,. Does osteocytic SOST suppression mediate PTH bone anabolism?. Trends Endocrinol Metab. 2010; 21: 237-44.
23. Potthoff MJ, Olson EN,. MEF2: a central regulator of diverse developmental programs. Development. 2007; 134: 4131-40.
24. McKinsey TA, Zhang CL, Olson EN,. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci. 2002; 27: 40-7. (Pubitemid 34131624)
25. Lin Q, Schwarz J, Bucana C, Olson EN,. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science. 1997; 276: 1404-7. (Pubitemid 27235406)
26. Arnold MA, Kim Y, Czubryt MP, Phan D, McAnally J, Qi X, Shelton JM, Richardson JA, Bassel-Duby R, Olson EN,. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev Cell. 2007; 12: 377-89.
27. Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, Richards JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Grundberg E, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra B, Pastinen T, Pols HA, Sigurdsson G, Soranzo N, Thorleifsson G, Thorsteinsdottir U, Williams FM, Wilson SG, Zhou Y, Ralston SH, van Duijn CM, Spector T, Kiel DP, Stefansson K, Ioannidis JP, Uitterlinden AG,. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet. 2009; 41: 1199-206.
28. Lu Y, Xie Y, Zhang S, Dusevich V, Bonewald LF, Feng JQ,. DMP1-targeted Cre expression in odontoblasts and osteocytes. J Dent Res. 2007; 86: 320-5.
29. Vong LH, Ragusa MJ, Schwarz JJ,. Generation of conditional Mef2cloxP/loxP mice for temporal- and tissue-specific analyses. Genesis. 2005; 43: 43-8. (Pubitemid 41377433)
30. Gu G, Nars M, Hentunen TA, Metsikko K, Vaananen HK,. Isolated primary osteocytes express functional gap junctions in vitro. Cell Tissue Res. 2006; 323: 263-71. (Pubitemid 43100268)
31. Kneissel M, Boyde A, Gasser JA,. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone. 2001; 28: 237-50. (Pubitemid 32192948)
32. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR,. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
33. Kneissel M,. The rise of osteocyte biology continues: meeting report from the 32nd Annual Meeting of the American Society for Bone and Mineral Research. IBMS BoneKEy. 2011; 8: 46-54.
34. Yavropoulou MP, Yovos JG,. Osteoclastogenesis-current knowledge and future perspectives. J Musculoskelet Neuronal Interact. 2008; 8: 204-16.
35. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF, Kneissel M,. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010; 30: 3071-85.
36. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G,. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8: 751-64. (Pubitemid 40585297)
37. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO,. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005; 280: 21162-8. (Pubitemid 40805677)
38. Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto D, Caothien RH, Fuller JH, Reinhard C, Garcia PD, Randazzo FM, Escobedo J, Fantl WJ, Williams LT,. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci USA. 2001; 98: 14973-8. (Pubitemid 34013954)
39. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F,. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 2002; 22: 1172-83. (Pubitemid 34094853)
40. Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S, Cho KR, Fearon ER,. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem. 2002; 277: 21657-65. (Pubitemid 34952316)
41. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM, Birchmeier W, Behrens J,. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol. 2002; 22: 1184-93. (Pubitemid 34094854)
42. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence MJ, Holcombe RF, Waterman ML,. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet. 2001; 28: 53-7. (Pubitemid 32405817)
43. Filali M, Cheng N, Abbott D, Leontiev V, Engelhardt JF,. Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter. J Biol Chem. 2002; 277: 33398-410. (Pubitemid 34984863)
44. Nagy A,. Cre recombinase: the universal reagent for genome tailoring. Genesis. 2000; 26: 99-109. (Pubitemid 30158089)
45. Dean AK, Harris SE, Kalajzic I, Ruan J,. A systems biology approach to the identification and analysis of transcriptional regulatory networks in osteocytes. BMC Bioinformatics. 2009; 10 (Suppl 9): S5.
46. Cripps RM, Lovato TL, Olson EN,. Positive autoregulation of the Myocyte enhancer factor-2 myogenic control gene during somatic muscle development in Drosophila. Dev Biol. 2004; 267: 536-47. (Pubitemid 38328591)
47. Ramachandran B, Yu G, Li S, Zhu B, Gulick T,. Myocyte enhancer factor 2A is transcriptionally autoregulated. J Biol Chem. 2008; 283: 10318-29.
48. Wang DZ, Valdez MR, McAnally J, Richardson J, Olson EN,. The Mef2c gene is a direct transcriptional target of myogenic bHLH and MEF2 proteins during skeletal muscle development. Development. 2011; 128: 4623-33.
49. Potthoff MJ, Wu H, Arnold MA, Shelton JM, Backs J, McAnally J, Richardson JA, Bassel-Duby R, Olson EN,. Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J Clin Invest. 2007; 117: 2459-67. (Pubitemid 47494347)
50. Potthoff MJ, Arnold MA, McAnally J, Richardson JA, Bassel-Duby R, Olson EN,. Regulation of skeletal muscle sarcomere integrity and postnatal muscle function by Mef2c. Mol Cell Biol. 2007; 27: 8143-51. (Pubitemid 350234229)
51. Liu C, Zhao Y, Cheung WY, Gandhi R, Wang L, You L,. Effects of cyclic hydraulic pressure on osteocytes. Bone. 2010; 46: 1449-56.
52. Silvestrini G, Ballanti P, Patacchioli F, Leopizzi M, Gualtieri N, Monnazzi P, Tremante E, Sardella D, Bonucci E,. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol. 2005; 36: 59-67. (Pubitemid 40614383)
53. You L, Temiyasathit S, Lee P, Kim CH, Tummala P, Yao W, Kingery W, Malone AM, Kwon RY, Jacobs CR,. Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone. 2008; 42: 172-9.
54. Zhao S, Zhang YK, Harris S, Ahuja SS, Bonewald LF,. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res. 2002; 17: 2068-79. (Pubitemid 35239208)
55. Frenkel B, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O, Gabet Y,. Regulation of adult bone turnover by sex steroids. J Cell Physiol. 2010; 224: 305-10.
56. Gannage-Yared MH, Fares F, Semaan M, Khalife S, Jambart S,. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf). 2006; 64: 652-8. (Pubitemid 43775003)
57. van Rooij E, Fielitz J, Sutherland LB, Thijssen VL, Crijns HJ, Dimaio MJ, Shelton J, De Windt LJ, Hill JA, Olson EN,. Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor. Circ Res. 2010; 106: 155-65.
58. Wyce A, Bai Y, Nagpal S, Thompson CC,. Research resource: the androgen receptor modulates expression of genes with critical roles in muscle development and function. Mol Endocrinol. 2010; 24: 1665-74.
59. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J,. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci. 2008; 121: 737-46. (Pubitemid 351578109)
60. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D,. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883-7. (Pubitemid 41379516)
61. Semenov M, Tamai K, He X,. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280: 26770-5. (Pubitemid 41040710)